pharma · Urothelial Carcinoma Bladder · Castration Resistant Metastatic Prostate Cancer · AKTS
Aktis Oncology
Aktis Oncology is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AKTS. Primary therapeutic focus areas include Urothelial Carcinoma Bladder, Castration Resistant Metastatic Prostate
Cambridge, USA HQ
90 Employees
Public company Type
AKTS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 90
- Programs
- 2
- Drugs
- 0
- Patents
- 1
[225Ac]Ac-AKY-2519 (therapeutic)
Phase 1 · small molecule · Castration Resistant Metastatic Prostate Cancer
[225Ac]Ac-AKY-2519 (therapeutic) for Castration Resistant Metastatic Prostate Cancer is a Phase 1 program (small_molecule) at Aktis Oncology with 1 ClinicalTrials.gov record(s).
Internal code AKY-2519-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aktis Oncology
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Castration Resistant Metastatic Prostate Cancer
- Status
- active
- Trials
- 1